Follow
Lipigon Pharmaceuticals AB
Nasdaq First North GM (Sweden)
Lipigon Pharmaceuticals AB develops medicines for diseases caused by disorders of the body's handling of fats. It focuses on orphan drugs for unusual diseases where there is no adequate treatment.
Sector:
HEALTH CARE
>
Biotechnology
Healthcare
News
Nothing to display for this company
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Type
Ticker
ISIN
Market
SHARE
LPGO
SE0015382072
Nasdaq First North GM
Sweden (SE)
Details of share in Lipigon Pharmaceuticals AB with ticker LPGO
Status
Active
Order book id
216630
Amount of instruments
9 732 898
Par value
Currency
SEK
Segment
First North
First trading date
01 Mar 2021
Type
Price
Pre-money valuation
Time
Files
IPO
11.20 SEK
53.01M SEK
25 Jan - 09 Feb 2021
IPO in Lipigon Pharmaceuticals AB
Type
Ticker
ISIN
Market
OPTION
LPGO TO1
SE0015482765
Nasdaq First North GM
Sweden (SE)
Details of option in Lipigon Pharmaceuticals AB with ticker LPGO TO1
Status
Active
Order book id
216631
Amount of instruments
5 000 000
Currency
SEK
Segment
First North
Trading period
01 Mar 2021 - 27 Apr 2022
Terms
One (1) warrant entitles the holder to subscribe for one (1) new share in the Company for SEK 14.6 per share during the subscription period from April 1, 2022 until April 30, 2022.
Type
Price
Pre-money valuation
Time
Files
Exercise
14.60 SEK
01 Apr - 30 Apr 2022
Option exercise terms for LPGO TO1
People
Stefan K Nilsson
CEO
Carina Schmidt
Chairman of the board
Lars Öhman
Board member
Mikael Elofsson
Board member
Jens Ålander
Board member
Company Details
Sector
HEALTH CARE
Website

Address
Tvistevägen 48 C
Zip code
907 36
City/district
Umeå
Country
Sweden (SE)
Registration number
556810-9077
LEI code
549300XPO40YR12SLY87
First trade date
01 Mar 2021
Registration date
07 Jun 2010
Short name
Lipigon

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More